Table 2 Definition of outcomes for the studies included in the meta-analysis
Author | Time to defervescence | Clinical failure | Mortality | Adverse drug effect | ||||
|---|---|---|---|---|---|---|---|---|
Below Temp (oC) | Sustained (hrs) | Antipyretics excluded | Thermometer | Frequency | Cut-off day for defervescence | |||
Varghese 2023 [18] | 37.5 | 24 | NA | Oral | q24h | 2 daysa | All-cause | Treatment-related ≥ Grade 3 |
Guan-Xiu-Gang 2022 [19] | 37.3 | 48 | NA | NA | NA | NR | ST related | NA |
Hwang 2022 [20] | 37.3 | 48 | Yes | NA | NA | 2 days | ST related | NA |
Kabir 2022 [21] | 37.3 | 48 | NA | axillary | Q4h | 3 days | NA | Any treatment related |
Arun Babu 2021 [22] | 37.5 | 24 | NA | NA | NA | 2 days | NA | NA |
Barnabas 2021 [23] | 37.7 | 72 | Yes | axillary | NA | 2 days | All-cause | NA |
Veerappan 2021 [24] | 37.2 | 48 | Yes | axillary | Q2h | 2 days | NA | NA |
Chanta 2015 [25] | 37.3 | 48 | NA | NA | NA | 3 days | NA | Any treatment related |
Phimda 2007 [26] | 37.5 | NA | Yes | oral | q4h | 2 daysa | NA | Any treatment related |
Kim 2004 [27] | 37.3 | 48 | Yes | oral | q2h | 2 daysa | NA | Reported |